Vertical: HealthcareBase Year: 202346 Sections
Market Size (2023)
—
Projected (2032)
—
CAGR (2019–2032)
N/A
Key Players
100+
This report covers US Computed Tomography (CT) Market with forecasts from 2019 to 2032. 100 key companies are profiled.
US Computed Tomography (CT) Market is a key focus area for market intelligence and strategic research.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansINTRODUCTION
The Significant investments in healthcare infrastructure are driving the US Computed Tomography (CT) Market. Furthermore, increasing incidences of chronic diseases, cancer, cardiovascular diseases, and neurological disorders are boosting the growth of the market. Additionally, the High Cost of CT Scanners and Reimbursement Challenges are restraining the growth of the US Computed Tomography (CT) Market. However, the Growing Demand for Portable & Point-of-Care CT Scanners and AI Integration in CT Imaging will provide growth opportunities for the market in the future.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2023
Historical Period
2019 – 2022
Forecast Period
2024 – 2032
Primary Interviews
150+
Historical data (2019–2023) and forecast period (2023–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Michael Porter's Five Forces model is a framework to study the US Computed Tomography (CT) Market. Strategic business managers trying to gain an edge over competing firms in the US Computed Tomography (CT) Market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the US Computed Tomography (CT) Market have been broken down and analysed.
PORTER'S FIVE FORCES ANALYSIs: US Computed Tomography (CT) Market
Threat of New Entrants
The U.S. Computed Tomography (CT) market has moderate entry barriers due to high capital requirements, stringent FDA regulations, and the dominance of established players. Large firms benefit from economies of scale, strong brand recognition, and extensive distribution networks, making it difficult for new entrants to compete.
However, opportunities exist for startups focusing on AI-driven imaging and cost-effective solutions. Government incentives and technological advancements may lower barriers, enabling niche players to enter the market. Despite challenges, new entrants with innovative approaches and strategic partnerships can carve out market segments, though competition with industry leaders remains a significant hurdle.
BARGAINING POWER OF SUPPLIERS
In the U.S. CT market, suppliers have a moderate level of bargaining power. While critical components like X-ray tubes, detectors, and computing systems are sourced from a limited number of specialized manufacturers, large CT companies mitigate supplier influence through long-term contracts, vertical integration, and multiple sourcing strategies. Regulatory compliance and high R&D costs limit new suppliers, maintaining some leverage for existing providers. However, major CT manufacturers have strong negotiation power due to their scale, reducing dependency on individual suppliers. Smaller CT manufacturers, however, may face higher costs and limited alternatives, leading to moderate supplier power across the industry.
Threat of Substitutes
The threat of substitutes in the U.S. CT market is high due to the availability of alternative imaging modalities such as MRI, ultrasound, and PET scans. MRI offers superior soft tissue contrast without radiation exposure, making it a preferred choice for neurological and musculoskeletal imaging. Ultrasound provides a cost-effective, radiation-free alternative for specific diagnostic applications. PET scans are crucial for oncology imaging. As healthcare providers prioritize patient safety and cost efficiency, these alternatives can limit CT scan demand. However, CT remains indispensable for trauma cases, lung imaging, and emergency diagnostics, maintaining its strong position despite growing substitution threats.
Bargaining Power of Buyers
Buyers in the U.S. CT market, including hospitals, diagnostic centers, and imaging clinics, exert high bargaining power due to their ability to negotiate pricing, service contracts, and maintenance agreements. Large healthcare providers and purchasing groups leverage bulk procurement to secure favorable terms. The availability of alternative imaging modalities, such as MRI and ultrasound, further strengthens buyer influence. Additionally, increasing cost pressures and reimbursement challenges push buyers to seek cost-effective solutions. While established CT manufacturers offer advanced technology, buyers can compare multiple vendors, intensifying competition and driving price sensitivity in the market.
Intensity of Rivalry
Intensity of Rivalry is high due to major players like GE Healthcare, Siemens Healthineers, and Philips dominating through technological advancements, extensive distribution networks, and strong brand recognition. Companies continuously innovate by enhancing image quality, reducing radiation doses, and integrating AI-driven diagnostics to differentiate their products. Price competition is intense, especially among hospitals and diagnostic centers seeking cost-effective solutions. Additionally, increasing demand for portable and high-speed CT scanners fuels competition. With frequent product launches, strategic partnerships, and aggressive marketing, industry rivalry remains high, creating challenges for smaller players trying to establish a foothold in the market.
IMPACT OF COVID-19 on US COMPUTED TOMOGRAPHY (CT) MARKET
The COVID-19 pandemic significantly influenced the U.S. CT scan market, driving both short-term disruptions and long-term changes in demand and technology adoption. Initially, the market experienced a decline in elective imaging procedures due to hospital resource reallocation and patient reluctance to visit healthcare facilities. However, the need for rapid and accurate lung imaging in COVID-19 patients increased demand for CT scans, particularly for detecting pneumonia and assessing disease severity.
During the peak of the pandemic, healthcare providers prioritized CT imaging for COVID-19 diagnostics, leading to increased utilization rates. This shift prompted many hospitals to upgrade or expand their CT scanner capacities. Additionally, AI-driven CT imaging solutions gained traction, improving diagnostic efficiency and reducing scan interpretation times.
Supply chain disruptions affected the availability of key CT components, leading to temporary delays in manufacturing and installation. However, as the market rebounded, hospitals and imaging centers resumed postponed procedures, boosting demand for CT systems.
Post-pandemic, the U.S. CT market continues to grow due to heightened awareness of respiratory illnesses, increased hospital preparedness, and advancements in AI integration for automated diagnostics. The pandemic also accelerated the adoption of mobile and portable CT scanners to support decentralized healthcare delivery. Overall, while COVID-19 initially disrupted the market, it ultimately reinforced the critical role of CT imaging in emergency care and long-term diagnostic planning.
Market Trends on US COMPUTED TOMOGRAPHY (CT) MARKET
The U.S. computed tomography (CT) market is experiencing significant growth, driven by technological advancements and an increasing prevalence of chronic diseases.
AI and Machine Learning Integration: The integration of Artificial Intelligence (AI) and Machine Learning (ML) in computed tomography (CT) is transforming the U.S. medical imaging industry. AI-driven solutions are enhancing diagnostic accuracy, automating workflows, and reducing scan times, ultimately improving patient outcomes. Advanced AI algorithms assist radiologists by detecting abnormalities such as tumors, fractures, and vascular conditions with greater precision and speed.
One of the key innovations is AI-powered image reconstruction, which enhances image clarity while minimizing radiation exposure. This is particularly beneficial for pediatric and high-risk patients. Additionally, AI applications in automated segmentation and classification streamline diagnosis, allowing for faster and more accurate reporting.
Machine learning also improves predictive analytics, enabling early disease detection and personalized treatment plans. AI-based workflow automation reduces radiologist fatigue by prioritizing critical cases, ensuring timely intervention. Furthermore, deep learning models are being integrated into decision-support systems, aiding in complex diagnostic scenarios.
As AI adoption continues to grow, regulatory bodies like the FDA are increasingly approving AI-driven CT solutions, facilitating market expansion. The combination of AI, big data, and cloud computing is set to revolutionize CT imaging, making it more efficient, accurate, and accessible.
Shift Toward Value-Based Healthcare: The U.S. healthcare system is increasingly adopting a value-based care model, emphasizing improved patient outcomes, cost efficiency, and high-quality diagnostics.
See plans for professionals or small and medium businesses.
Analytical insights on US Computed Tomography (CT) Market covering market dynamics, competitive landscape, and strategic outlook.
US Computed Tomography (CT) Market represents a significant market opportunity with multiple growth drivers across regions and segments.
INTRODUCTION
The Significant investments in healthcare infrastructure are driving the US Computed Tomography (CT) Market. Furthermore, increasing incidences of chronic diseases, cancer, cardiovascular diseases, and neurological disorders are boosting the growth of the market. Additionally, the High Cost of CT Scanners and Reimbursement Challenges are restraining the growth of the US Computed Tomography (CT) Market. However, the Growing Demand for Portable & Point-of-Care CT Scanners and AI Integration in CT Imaging will provide growth opportunities for the market in the future.
increasing incidences of chronic diseases
The U.S. Computed Tomography (CT) market is experiencing significant growth, driven largely by the rising prevalence of chronic diseases. As per the Centers for Disease Control and Prevention in 2024, approximately 129 million Americans are living with at least one chronic condition, representing nearly 42% of the adult population. This trend is expected to escalate, with projections indicating that by 2030, the number could reach 170 million. Chronic diseases such as heart disease, diabetes, and cancer are increasingly impacting healthcare systems, necessitating advanced diagnostic imaging solutions.
As these health issues become more widespread, the demand for early and accurate diagnosis has intensified, making CT imaging an essential tool in modern medicine. The aging population, which is more susceptible to chronic illnesses, further contributes to the increasing utilization of CT scans in hospitals, diagnostic centers, and outpatient clinics.
Moreover, Technological advancements have significantly enhanced CT imaging capabilities. Low-dose CT (LDCT) technology minimizes radiation exposure, making scans safer for patients, while AI-driven image analysis improves diagnostic accuracy and workflow efficiency. Preventive healthcare initiatives, such as LDCT lung cancer screening recommended by the U.S. Preventive Services Task Force (USPSTF), are further driving adoption. Moreover, the increasing use of CT in cardiac imaging for detecting coronary artery diseases is expanding the market's reach.
Expansion of CT in Trauma & Emergency Care
The expansion of Computed Tomography (CT) in trauma and emergency care is driven by rising trauma cases, advancements in CT technology, and increasing investments in emergency healthcare infrastructure. As per the National Highway Traffic Safety Administration (NHTSA), U.S. records over 6 million road accidents annually, making CT the gold standard for diagnosing internal injuries, fractures, and brain trauma in emergency settings.
Additionally, the increasing prevalence of stroke and cardiovascular emergencies, with over 800,000 stroke cases each year, has fueled demand for CT angiography (CTA) and perfusion imaging, which enable rapid stroke detection and treatment planning. Similarly, coronary CT angiography (CCTA) is playing a crucial role in diagnosing acute chest pain and assessing coronary artery disease (CAD).
Moreover, Technological advancements in CT scanners, allow for ultra-fast imaging with high resolution, significantly improving diagnostic accuracy in emergency departments. The development of dual-energy and spectral CT further enhances tissue differentiation, making it easier to detect haemorrhages, vascular abnormalities, and subtle traumatic injuries.
Additionally, the rise of mobile and portable CT scanners is transforming emergency care by enabling on-site imaging in ICUs, ambulances, and military settings, ensuring faster diagnosis for critically ill patients. Point-of-care (POC) CT scanners are particularly beneficial for detecting traumatic brain injuries (TBI) and spinal injuries without the need to transfer unstable patients. Government and private investments in stroke-ready hospitals and trauma centers have also accelerated the adoption of high-end AI-integrated CT imaging systems, improving workflow efficiency and patient outcomes. As the demand for faster, more precise, and accessible imaging continues to rise, CT remains an indispensable tool in modern trauma and emergency care.
integration in CT imaging is creating significant opportunities in the U.S. CT scan market by enhancing diagnostic capabilities, optimizing workflows, and improving patient outcomes. The adoption of AI-powered algorithms enables radiologists to detect subtle abnormalities, such as tumors, fractures, and organ anomalies, with higher accuracy and speed. This is particularly beneficial in critical care settings, where rapid and precise diagnosis is crucial. By assisting in automated image interpretation and real-time analysis, AI reduces human error and improves the consistency of diagnoses, contributing to better clinical decision-making and enhanced patient care. One of the key opportunities AI brings is the ability to perform low-dose CT scans without compromising image quality. As radiation exposure remains a concern, AI helps optimize scan protocols, making CT safer for patients, especially in pediatric and geriatric populations. AI can also enhance workflow efficiency by reducing the time needed for image processing and interpretation, thus allowing radiologists to handle more cases in less time. Furthermore, AI-driven predictive analytics can assist in early disease detection, such as in lung cancer screening, by identifying risks before they become clinically apparent.
This creates opportunities for preventive healthcare initiatives and early intervention programs, helping reduce healthcare costs in the long run. idoc, a lo al leader in clinical, has develo ed ™ linical Reasoning Engine, Version 1), a groundbreaking clinical-grade foundation model for CT imaging. This is the first step in Aidoc's multi-year investment in the linical easonin n ine ™ frame ork As healthcare providers increasingly invest in AI- integrated CT systems, the U.S. CT scan market is positioned for rapid growth, offering both technological and clinical benefits. & POINT - OF-CARE CT SCANNERS The growing demand for portable and point-of-care (POC) CT scanners is reshaping the U.S. CT scan market by offering more accessible, flexible, and efficient imaging solutions. Portable CT scanners, designed to be compact and mobile, enable on-site imaging in diverse settings such as emergency departments, intensive care units (ICUs), ambulances, and even military environments. This mobility allows for immediate diagnosis without requiring the patient to be transported to a traditional imaging centre, which is particularly crucial for critically ill or trauma patients. A new compact ultrasound system from Philips was introduced at RSNA 2022, enabling more patients to receive the correct diagnosis the first time.
In addition, POC CT scanners are increasingly used in remote and underserved areas, where access to advanced imaging equipment may be limited. These systems improve patient outcomes by enabling quick diagnostic decisions, especially in emergency care and trauma settings, where time-sensitive interventions are necessary. As healthcare facilities look to streamline their operations and offer faster diagnostics, the integration of portable CT solutions is expanding. The ability to reduce waiting times, enhance workflow efficiency, and provide real-time imaging contributes significantly to the adoption of these devices. Moreover, with advances in battery life, image quality, and cost-efficiency, portable and POC CT scanners are becoming increasingly viable for healthcare providers, further driving demand in the U.S. market.
Shortage of Skilled Radiologists and Technicians
The shortage of skilled radiologists and technicians is a significant challenge for the healthcare industry, particularly in the field of computed tomography (CT) imaging. This shortage is driven by factors such as the increasing demand for diagnostic imaging, an aging workforce, and insufficient training programs to meet the growing needs of modern healthcare systems. As the population ages and the prevalence of chronic diseases rises, the demand for imaging services, including CT scans, has surged. However, the supply of qualified radiologists and technicians has struggled to keep pace, creating a bottleneck in imaging workflows and leading to longer waiting times for patients.
The shortage is exacerbated by the complexity of new technologies, such as AI-driven imaging systems and advanced CT techniques, which require specialized training. Radiologists and technicians need to continuously update their skills to stay current with these innovations, yet there are limited educational resources and training opportunities. This not only affects diagnostic accuracy but also puts additional pressure on healthcare providers, leading to burnout and stress among existing staff.
To address this issue, healthcare institutions are increasingly turning to automation and AI to assist in image interpretation and workflow management. Teleradiology services are also expanding, enabling radiologists to interpret images remotely, alleviating some of the workforce challenges. However, the shortage remains a significant barrier to optimal care, requiring ongoing investment in training, recruitment, and technology solutions.
Competition from Alternative Imaging Modalities
Competition from alternative imaging modalities poses a challenge to the growth of the computed tomography (CT) market. Technologies such as Magnetic Resonance Imaging (MRI), ultrasound, and Positron Emission Tomography (PET) offer alternative solutions that can sometimes provide equal or superior diagnostic results in specific cases. MRI, for example, is often preferred for soft tissue imaging due to its high-resolution capabilities and lack of ionizing radiation, making it a Favorable choice for certain neurological, musculoskeletal, and cardiovascular conditions. Ultrasound, being non-invasive, portable, and cost-effective, is widely used in obstetrics and emergency care, particularly for assessing trauma-related injuries in real-time.
Additionally, PET imaging is increasingly being used in oncology, as it can provide metabolic information about tumors, making it complementary to CT in cancer detection. These alternative modalities, combined with advances in hybrid imaging technologies, such as PET/CT and MRI/CT, create strong competition for the CT market.
As healthcare providers look to offer more cost-effective, patient-friendly, and accurate diagnostic solutions, the competition from these imaging technologies challenges the widespread adoption of CT. To remain competitive for the CT market.
AI integration in CT imaging is creating significant opportunities in the U.S. CT scan market by enhancing diagnostic capabilities, optimizing workflows, and improving patient outcomes. The adoption of AI-powered algorithms enables radiologists to detect subtle abnormalities, such as tumors, fractures, and organ anomalies, with higher accuracy and speed. This is particularly beneficial in critical care settings, where rapid and precise diagnosis is crucial. By assisting in automated image interpretation and real-time analysis, AI reduces human error and improves the consistency of diagnoses, contributing to better clinical decision-making and enhanced patient care.
One of the key opportunities AI brings is the ability to perform low-dose CT scans without compromising image quality. As radiation exposure remains a concern, AI helps optimize scan protocols, making CT safer for patients, especially in pediatric and geriatric populations. AI can also enhance workflow efficiency by reducing the time needed for image processing and interpretation, thus allowing radiologists to handle more cases in less time.
Furthermore, AI-driven predictive analytics can assist in early disease detection, such as in lung cancer screening, by identifying risks before they become clinically apparent. This creates opportunities for preventive healthcare initiatives and early intervention programs, helping reduce healthcare costs in the long run. Aidoc, a global leader in clinical AI, has developed CARE1™ (Clinical AI Reasoning Engine, Version 1), a groundbreaking clinical-grade foundation model for CT imaging. This is the first step in Aidoc's multi-year investment in the Clinical AI Reasoning Engine (CARE™) framework. As healthcare providers increasingly invest in AI-integrated CT systems, the U.S. CT scan market is positioned for rapid growth, offering both technological and clinical benefits.
Growing Demand for Portable & Point-of-Care CT Scanners
The growing demand for portable and point-of-care (POC) CT scanners is reshaping the U.S. CT scan market by offering more accessible, flexible, and efficient imaging solutions. Portable CT scanners, designed to be compact and mobile, enable on-site imaging in diverse settings such as emergency departments, intensive care units (ICUs), ambulances, and even military environments. This mobility allows for immediate diagnosis without requiring the patient to be transported to a traditional imaging centre, which is particularly crucial for critically ill or trauma patients. A new compact ultrasound system from Philips was introduced at RSNA 2022, enabling more patients to receive the correct diagnosis the first time.
In addition, POC CT scanners are increasingly used in remote and underserved areas, where access to advanced imaging equipment may be limited. These systems improve patient outcomes by enabling quick diagnostic decisions, especially in emergency care and trauma settings, where time-sensitive interventions are necessary.
As healthcare facilities look to streamline their operations and offer faster diagnostics, the integration of portable CT solutions is expanding. The ability to reduce waiting times, enhance workflow efficiency, and provide real-time imaging contributes significantly to the adoption of these devices.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 100 companies operating in the US Computed Tomography (CT) Market market, including revenue, employee count, and market positioning where available.
Showing 100 of 100 companies
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Eli Lilly is a research-based, vertically integrated pharmaceutical manufacturer that discovers, develops, manufactures and markets prescription medicines in a single reported business segment: human pharmaceutical products. Its commercial identity has been transformed since 2022 by the incretin class: tirzepatide, a dual GIP/GLP-1 receptor agonist, and from April 2026 orforglipron, an orally bioavailable non-peptide GLP-1 agonist. These assets have made Lilly the dominant player in the fastest-growing therapeutic category in pharmaceutical history, and have funded a step-change in capital deployment — more than $50 billion of announced U.S. manufacturing investment since 2020, $13.3 billion of FY2025 R&D spend, and more than a dozen acquisitions in 2026 alone. Around that core the company sustains four other franchises — oncology, immunology, neuroscience and legacy diabetes — and a direct-to-patient platform, LillyDirect. Lilly's central strategic bet is that obesity becomes a chronic-care category of unprecedented scale, and that it can own the supply, the pricing architecture and the next three generations of molecules within it. Eli Lilly and Company is, as of September 2026, the largest pharmaceutical company in the world by market capitalisation and the fastest-growing large-cap drug manufacturer by revenue. The company crossed the $1 trillion market-capitalisation threshold during 2025 — the first biopharmaceutical company ever to do so — on the strength of a single molecule, tirzepatide, commercialised under two brands (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnoea) that together generated $36.5 billion of revenue in FY2025. In April 2026 the company added the first small-molecule oral GLP-1 receptor agonist approved for obesity, Foundayo (orforglipron), to that franchise. --- ### The company's own characterisation Lilly describes itself in the FY2025 Form 10-K as a company that discovers, develops, manufactures and markets products in a single business segment — human pharmaceutical products — and states that most of the products it sells today were discovered or developed by its own scientists, with long-term success depending on the ability to continually discover or acquire, develop and commercialise innovative medicines. It manufactures and distributes through facilities in the United States (including Puerto Rico) and in Europe and Asia, and sells in approximately 105 countries. In its standard corporate boilerplate (Q2 2026 earnings release) Lilly positions itself as "a medicine company turning science into healing," with a 150-year history and scientific focus areas described as redefining diabetes care; treating obesity and curtailing its long-term complications; advancing the fight against Alzheimer's disease; addressing immune system disorders; and transforming difficult-to-treat cancers into manageable diseases. ### Independent characterisation Lilly is best understood today as three overlapping businesses operating under one P&L: **(a) The incretin platform (roughly 74% of FY2025 revenue).** Tirzepatide (Mounjaro + Zepbound) alone contributed $36.5 billion in FY2025, growing to a first-half 2026 run-rate of $27.7 billion across the two brands. Adding orforglipron (Foundayo, $98 million in its first partial quarter), legacy insulins, Trulicity and the Boehringer-partnered SGLT2/DPP-4 products, cardiometabolic health accounted for approximately $48.2 billion of FY2025 revenue. This is a volume business with unusually strong operating leverage: gross margin on the incretin portfolio has driven consolidated gross margin from 75.4% in FY2021 to 86.3% (non-GAAP) in Q2 2026, even as realised prices fell 13% year-on-year in that quarter. **(b) The diversified specialty portfolio (roughly 24% of FY2025 revenue).** Oncology ($9.4 billion), immunology ($5.2 billion) and neuroscience ($1.4 billion) constitute a conventional branded-pharma business with a normal mix of growth assets (Jaypirca, Ebglyss, Omvoh, Kisunla, Inluriyo) and mature or declining ones (Cyramza, Emgality, Taltz, Olumiant). Management has explicitly flagged this cluster as its diversification hedge: key-product revenue in immunology, oncology and neuroscience grew 121% year-on-year in Q2 2026. **(c) A capital-deployment engine.** With $16.8 billion of FY2025 operating cash flow rising to a $28.1 billion trailing-twelve-month figure at June 2026, Lilly has become one of the most acquisitive companies in the sector — at least thirteen acquisitions announced in 2026 through August — and the largest single builder of pharmaceutical manufacturing capacity in U.S. history. ### Revenue model and value-chain position Lilly's revenue is overwhelmingly product revenue. Approximately 93.5% of FY2025 revenue was product sales, with the balance (approximately $4.2 billion) collaboration and other revenue, principally from the Boehringer Ingelheim diabetes alliance, the Incyte relationship on Olumiant, royalty streams and sales-based milestones. There is no subscription revenue; "service" revenue is immaterial. The company occupies an unusually deep position in its value chain for a modern large-cap pharma: it manufactures its own active pharmaceutical ingredients, fills and finishes its own injectable devices, and, since January 2024, sells directly to patients through LillyDirect, bypassing parts of the traditional wholesaler-pharmacy-PBM chain for self-pay volumes. **Customer types and end-markets.** The direct customers are wholesalers and distributors (McKesson, Cencora, Cardinal Health in the U.S.), retail and specialty pharmacy chains, hospital systems, government purchasers (Medicare Part D plans, Medicaid programs, the Veterans Health Administration, and from 2026 the TrumpRx platform), managed-care organisations and pharmacy benefit managers, and — increasingly — patients paying cash through LillyDirect and affiliated telehealth partners. End-markets are obesity and metabolic disease, type 2 diabetes, oncology, immunology/inflammation, neurodegeneration and pain.
Sanofi is a top-tier global biopharmaceutical company that has, over six years, deliberately narrowed itself from a diversified healthcare conglomerate into a single-segment, R&D-led specialty medicines and vaccines business. Its centre of gravity is immunology: Dupixent, co-developed with Regeneron, generated €15.7bn in FY2025 — 36% of group sales — and management now guides to approximately €25bn by 2030. Around that core sit a differentiated rare-disease franchise (Pompe, Gaucher, Fabry, haemophilia, ASMD), the world's broadest vaccines portfolio outside Merck and GSK, and a smaller oncology and neurology presence. The company shed EUROAPI in 2022 and sold control of Opella consumer health to CD&R in 2025 for €10.4bn net. Financially it is unusually clean — 77.5% business gross margin, 0.8x net debt/EBITDA, 31 consecutive years of dividend increases. The unresolved question, and the reason for a February 2026 CEO change, is whether its internal pipeline can replace Dupixent's eventual erosion. *Caveat: Sanofi does not publish a single headline headcount in its quarterly releases. The FY2021 figure derives from the company's 2022 employee share plan disclosure ("over 90,000 employees in 73 countries" eligible in 2021); the FY2024/FY2025 figure of ~83,000 is the company-sourced number cited in industry reporting at the time of the March 2025 US investment announcement, reflecting both restructuring and the Opella separation. Precise year-end FTE counts are disclosed in the Universal Registration Document / Form 20-F and are not restated here. The 2025 employee share plan was offered to "around 70,000 employees in 55 countries" — an eligibility population, not total headcount.* --- ### What Sanofi does Sanofi researches, develops, manufactures and commercialises prescription medicines and human vaccines. Since January 1, 2025 it reports one operating segment, Biopharma, plus an immaterial "Other" line that captures residual Opella-related transitional revenues and manufacturing services. Sanofi's own characterisation, used verbatim in every 2026 press release, is: *"Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world."* The formal segment description in its 2025 shelf-registration prospectus reads: *"We have one operating segment: Biopharma. It comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories."* Internally, and in the reporting taxonomy adopted from FY2025, the business is organised as: - **Pharma** - *Immunology* — Dupixent, Kevzara - *Rare diseases* — Fabrazyme, Cerezyme/Cerdelga, Myozyme/Nexviazyme, Aldurazyme, Xenpozyme, ALTUVIIIO, Eloctate, Alprolix, Cablivi, Qfitlia, Wayrilz, Ayvakit - *Neurology* — Aubagio (in run-off), Cenrifki (tolebrutinib) - *Oncology* — Sarclisa, Jevtana, Fasturtec - *Other main / established medicines* — Lantus, Toujeo, Apidra, Soliqua, Plavix, Lovenox, Aprovel, Multaq, Praluent, Thymoglobulin, Rezurock, Synvisc - **Vaccines** — influenza (Fluzone/Efluelda/Vaxigrip), polio/pertussis/Hib (Pentacel, Pentaxim, Hexaxim, Vaxelis via JV), meningitis (Menactra, MenQuadfi), travel/endemic (rabies, yellow fever, typhoid, hepatitis A), Beyfortus (RSV mAb, with AstraZeneca), Nuvaxovid (COVID-19), Heplisav-B (adult hepatitis B, acquired with Dynavax) ### Revenue model Sanofi's revenue is overwhelmingly product sales of patented and off-patent pharmaceuticals and vaccines — there is effectively no subscription or service revenue. The economics have four distinct layers: 1. **Net sales (€43,626m FY2025)** — gross invoiced product sales less gross-to-net deductions (US rebates, Medicaid/340B, chargebacks, ex-US statutory price cuts, China VBP/NRDL). 2. **Other revenues (€3,090m FY2025)** — a materially different-margin stream comprising VaxServe's distribution of *non-Sanofi* vaccines in the US (€1,780m FY2025, declining), manufacturing services (€557m), transitional sales of Opella products in certain markets (€487m), and royalties (€146m). 3. **Alliance profit-sharing, recorded in other operating income/expenses** — this is the single most important non-obvious feature of Sanofi's P&L. Sanofi books 100% of worldwide Dupixent and Kevzara sales but must then pay Regeneron its share of alliance profit. In FY2025 the total charge related to Regeneron was €4,923m, of which €5,065m was the monoclonal-antibody alliance net (profit/loss share −€5,455m, plus €1,089m of Regeneron's contribution to development costs, less €699m reimbursement of Regeneron commercial operating expenses). This charge grew 28% year-on-year and structurally caps Sanofi's operating leverage on its fastest-growing asset. 4. **Out-licensing royalties** — notably the Amvuttra royalty (€398m in H1 2026, up from €120m in H1 2025) and other license-out income (€495m FY2025). ### Value chain position and customers Sanofi is a fully integrated originator: discovery research, clinical development, regulatory, primary and secondary manufacturing (biologics, sterile injectables, vaccine bulk and fill-finish), and direct commercialisation in most markets. It also operates VaxServe, a US vaccine and specialty-pharmaceutical distribution business that carries third-party product — a rare downstream extension. Customers are institutional rather than retail: US wholesalers (McKesson, Cencora, Cardinal) and PBMs, national and regional health systems and tender authorities in Europe, public immunisation programmes and supranational buyers (UNICEF, PAHO, Gavi) for vaccines, hospital groups, and specialty pharmacies for rare disease and biologic products. End-markets are immunology and inflammation, rare genetic disease, haematology, multiple sclerosis, multiple myeloma, diabetes, cardiovascular disease, and paediatric and adult immunisation. ### Independent characterisation Functionally Sanofi is now one very large product (Dupixent) plus a durable but low-growth annuity book plus an option on a rebuilt pipeline. Dupixent contributed 36% of FY2025 net sales and 44.4% of Q2 2026 net sales, and grew 37.6% in Q2 2026 — meaning group growth is almost entirely one franchise. The vaccines business, historically Sanofi's defensive ballast, has become a source of volatility: it declined 1.2% in FY2025 and 1.1% in H1 2026, pressured by falling birth rates in China, US immunisation-policy uncertainty, and competitive tendering. The rare-disease and haemophilia portfolios are genuinely differentiated but individually sub-scale. The strategic problem management is now addressing is that Sanofi has bought growth (Blueprint, Dynavax, Vicebio) faster than it has generated it internally — and in July 2026 discontinued three of the assets that were supposed to be the answer.
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.
8 interactive charts drawn from the US Computed Tomography (CT) Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
US Computed Tomography (CT) Market By State
US Computed Tomography (CT) Market By Distribution Channel
US Computed Tomography (CT) Market By End User
US Computed Tomography (CT) Market By Application
US Computed Tomography (CT) Market By Conventional Scanners
US Computed Tomography (CT) Market By South
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
